Pharmacological chaperone therapy with high-dose oral ambroxol shows promise in treating neuronopathic GD, necessitating further clinical trials.
No takes yet. Share an insight, caveat, or question.
Narita et al. (2016) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: